Literature DB >> 18094135

Dual-reporter phenotypic assay for human immunodeficiency viruses.

Keiko Kajiwara1, Eiichi Kodama, Yasuko Sakagami, Takeshi Naito, Masao Matsuoka.   

Abstract

We have established a novel human immunodeficiency virus (HIV) tandem-reporter assay using HIV receptor-transduced NP-2 cells with long terminal repeat-controlled beta-galactosidase, inserted internal ribosome entry site, and secretary alkaline phosphatase genes. This assay allows users to detect replication of clinical isolates, indicating its useful application as an HIV phenotypic assay.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18094135      PMCID： PMC2238070          DOI： 10.1128/JCM.01470-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  37 in total

Review 1.  Principles of HIV resistance testing and overview of assay performance characteristics.

Authors:  D D Richman
Journal:  Antivir Ther       Date:  2000-03

2.  Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.

Authors:  M R Loutfy; J M Raboud; J S G Montaner; T Antoniou; B Wynhoven; F Smaill; D Rouleau; J Gill; W Schlech; Z L Brumme; T Mo; K Gough; A Rachlis; P R Harrigan; S L Walmsley
Journal:  Antiviral Res       Date:  2006-12-18       Impact factor: 5.970

Review 3.  Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.

Authors:  G J Hanna; R T D'Aquila
Journal:  Clin Infect Dis       Date:  2001-02-28       Impact factor: 9.079

4.  Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.

Authors:  W Y Gao; R Agbaria; J S Driscoll; H Mitsuya
Journal:  J Biol Chem       Date:  1994-04-29       Impact factor: 5.157

5.  Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates.

Authors:  R W Shafer; M J Kozal; D A Katzenstein; W H Lipil; I F Johnstone; T C Merigan
Journal:  J Virol Methods       Date:  1993-03       Impact factor: 2.014

6.  Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine.

Authors:  L M Frenkel; L E Wagner; S M Atwood; T J Cummins; S Dewhurst
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

7.  Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.

Authors:  Thomas J Ketas; Shawn E Kuhmann; Ashley Palmer; Juan Zurita; Weijing He; Sunil K Ahuja; Per Johan Klasse; John P Moore
Journal:  Virology       Date:  2007-04-10       Impact factor: 3.616

8.  Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Rebekah Barr; Vinay K Pathak
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

9.  Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.

Authors:  Jessica H Brehm; Dianna Koontz; Jeffrey D Meteer; Vinay Pathak; Nicolas Sluis-Cremer; John W Mellors
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

10.  Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1.

Authors:  H Salomon; A Belmonte; K Nguyen; Z Gu; M Gelfand; M A Wainberg
Journal:  J Clin Microbiol       Date:  1994-08       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.